DDInter899 DDInter1949
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide. It was developed by Global Blood Therapeutics, Inc. and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]
Voxelotor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Voxelotor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Voxelotor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Voxelotor {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Voxelotor may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Voxelotor may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Voxelotor may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Voxelotor may lead to a major life threatening interaction when taken with Apalutamide